We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study.
- Authors
Kita, Mariko; Fox, Robert J; Phillips, J Theodore; Hutchinson, Michael; Havrdova, Eva; Sarda, Sujata P; Agarwal, Sonalee; Kong, Jessica; Zhang, Annie; Viglietta, Vissia; Sheikh, Sarah I; Seidman, Emily; Dawson, Katherine T
- Abstract
Multiple sclerosis (MS) has a significant impact on health-related quality of life (HRQoL) with symptoms adversely affecting many aspects of everyday living. BG-12 (dimethyl fumarate) demonstrated significant efficacy in the phase III studies DEFINE and CONFIRM in patients with relapsing–remitting MS. In CONFIRM, HRQoL was worse in patients with greater disability at baseline, and who relapsed during the study, and improved with BG-12 treatment. Mean Short Form-36 Physical Component Summary scores for BG-12 increased over 2 years and scores for placebo decreased. Coupled with clinical and neuroradiological benefits, these HRQoL results further support BG-12 as an effective oral treatment for relapsing MS.
- Subjects
MULTIPLE sclerosis research; BISOPROLOL; GLATIRAMER acetate; QUALITY of life; DEMYELINATION; THERAPEUTICS
- Publication
Multiple Sclerosis Journal, 2014, Vol 20, Issue 2, p253
- ISSN
1352-4585
- Publication type
Article
- DOI
10.1177/1352458513507818